Abstract Number: 2708 • 2019 ACR/ARP Annual Meeting
Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials
Background/Purpose: Patients (pts) with polyarticular-course JIA (pJIA) may develop anti-drug antibodies (ADAs) in response to biologics.1 Presence of ADAs has been associated with treatment (tmt)…Abstract Number: 546 • 2019 ACR/ARP Annual Meeting
Change in Rheumatoid Arthritis (RA)-Related Autoantibody Profile and Risk of Disease Flare After Withdrawal of Therapy in Patients with Early RA Treated with Abatacept and MTX
Background/Purpose: An emerging concept of “immunologic remission” in RA raises questions about the relevance of the RA autoantibody profile in patients (pts) who are otherwise…Abstract Number: 2770 • 2019 ACR/ARP Annual Meeting
Towards the Lowest Efficacious Dose (ToLEDo): Results of a Multicenter Non-Inferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis Patients in Remission
Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARD) tapering is proposed by clinical practice guidelines in rheumatoid arthritis (RA) patients in sustained remission. However, no randomized…Abstract Number: 1389 • 2019 ACR/ARP Annual Meeting
Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry
Background/Purpose: ACR guidelines recommend treatment for patients with RA based on baseline (BL) disease activity. In patients with an inadequate response to conventional synthetic DMARDs,…Abstract Number: 2915 • 2019 ACR/ARP Annual Meeting
Machine-learning Classification Identifies a Subset of Patients That Improve on Abatacept via Modulation of a CD28-Related Pathway
Background/Purpose: We analyzed a phase 2 study designed to assess the efficacy of abatacept in patients with diffuse Systemic Sclerosis (SSc). In this work, we…Abstract Number: 1394 • 2019 ACR/ARP Annual Meeting
Association Between Baseline Anti-CCP2 Antibody Concentration and Clinical Response After 6 Months of Treatment with Abatacept or a TNF Inhibitor in Biologic-Experienced Patients with RA: Results from a US National Observational Study
Background/Purpose: In the AMPLE trial, patients (pts) with RA with higher baseline anti-CCP2 antibody concentrations showed a better response to treatment with abatacept (ABA) than…Abstract Number: 1411 • 2019 ACR/ARP Annual Meeting
Positivity of Anti-Ro/SSA Antibody Confer Poor Response and Persistence with Abatacept Therapy
Background/Purpose: Rheumatoid arthritis (RA) occasionally overlaps Sjogren’s syndrome (SS), and RA patients with secondary SS have a higher disease activity of RA and worse joint…Abstract Number: 1422 • 2019 ACR/ARP Annual Meeting
Reduction in CD4 TEMRA Cells and Its Association with DAS28 (CRP) < 2.6 Treatment Response with Abatacept in Patients with Early, ACPA+, DMARD-Naïve RA
Background/Purpose: T-cell profiles are heterogeneous between individuals and consist of naïve T cells, memory T cells (including effector memory T cells [TEM] and central memory…Abstract Number: 1423 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study
Background/Purpose: Early biologic use can improve long-term control of RA, and early use of abatacept (ABA) + MTX has demonstrated sustained improvements in selected patient-reported…Abstract Number: 1424 • 2019 ACR/ARP Annual Meeting
The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naïve Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial
Background/Purpose: Mechanistic differences between biologic DMARDs are poorly understood. Exploring these mechanisms includes assessing the role of HLA-DRB1 alleles containing the shared epitope (SE), which…Abstract Number: 1105 • 2018 ACR/ARHP Annual Meeting
Abatacept Is Effective in Experimental Digestive and Lung Tissue Fibrosis
Background/Purpose: A previous report showed that abatacept (IgG-CTLA-4) prevented and induced regression of inflammation-driven dermal fibrosis in two different mouse models of systemic sclerosis (SSc)…Abstract Number: 1543 • 2018 ACR/ARHP Annual Meeting
The Efficacy, Safety and Adherence of Biologicbiological Disease-Modifying Anti Rheumatic Drugs, Infliximab, Tocilizumab and Abatacept, in Elderly Patients with Rheumatoid Arthritis
Background/Purpose: Elderly patients with rheumatoid arthritis (RA) have declined physical performances and increased various complications. We are concerned about decrease of efficacy and increase of…Abstract Number: 1716 • 2018 ACR/ARHP Annual Meeting
Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis in a Phase II Trial of Abatacept Vs. Placebo
Background/Purpose: Treatment with CTLA4Ig, abatacept (ABA), in early diffuse cutaneous systemic sclerosis (dcSSc; the Phase 2 ASSETtrial) showed evidence of improvements in modified Rodnan skin…Abstract Number: 2378 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category
Background/Purpose: The effect of biologic DMARDs on different juvenile idiopathic arthritis (JIA) categories is poorly understood. In patients (pts) with JIA aged 2–17 years (y),…Abstract Number: 2383 • 2018 ACR/ARHP Annual Meeting
Pharmacovigilance of Biologics for Non-Systemic Juvenile Idiopathic Arthritis By the German Biologics Registry
Background/Purpose: Long-term surveillance of biologics is particularly important in pediatric patients (pts) who may require prolonged treatment. Since 2001, the German Biologics JIA Registry (BIKER)…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 12
- Next Page »